William Raj Sellers, M.D. - Publications

Affiliations: 
Novartis, Basel, Basel-Stadt, France 
Area:
oncology

181 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, ... ... Sellers WR, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10: 4346. PMID 31554815 DOI: 10.1038/s41467-019-12361-9  0.52
2019 Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, ... ... Sellers WR, et al. The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860. PMID 31068703 DOI: 10.1038/s41591-019-0404-8  0.52
2019 Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Sellers WR, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/s41586-019-1186-3  0.52
2018 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. PMID 30559381 DOI: 10.1038/s41586-018-0722-x  1
2016 Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, et al. High order drug combinations are required to effectively kill colorectal cancer cells. Cancer Research. PMID 27659046 DOI: 10.1158/0008-5472.CAN-15-3425  0.52
2016 Chen YP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, ... ... Sellers WR, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. PMID 27362227 DOI: 10.1038/nature18621  1
2016 Garcia Fortanet J, Chen CH, Chen YP, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C, Grunenfelder D, Ho S, Kang ZB, Karki R, Kato M, ... ... Sellers WR, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. Journal of Medicinal Chemistry. PMID 27347692 DOI: 10.1021/acs.jmedchem.6b00680  1
2016 Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, ... ... Sellers WR, et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discovery. PMID 27260157 DOI: 10.1158/2159-8290.CD-16-0178  1
2016 Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, ... ... Sellers WR, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife. 5. PMID 27183006 DOI: 10.7554/eLife.13964  1
2016 Mirzaa GM, Campbell CD, Solovieff N, Goold CP, Jansen LA, Menon S, Timms AE, Conti V, Biag JD, Olds C, Boyle EA, Collins S, Ishak G, Poliachik SL, Girisha KM, ... ... Sellers WR, et al. Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism. Jama Neurology. PMID 27159400 DOI: 10.1001/jamaneurol.2016.0363  1
2016 Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, ... ... Sellers WR, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine. 22: 464-71. PMID 27149219 DOI: 10.1038/nm.4089  1
2016 Mavrakis KJ, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, ... ... Sellers WR, et al. Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5. Science (New York, N.Y.). PMID 26912361 DOI: 10.1126/science.aad5944  1
2016 Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, ... ... Sellers WR, et al. Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. Plos One. 11: e0146635. PMID 26731447 DOI: 10.1371/journal.pone.0146635  0.32
2015 Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 4: e176. PMID 26657580 DOI: 10.1038/oncsis.2015.39  1
2015 Herkert B, Kauffmann A, Mollé S, Schnell C, Ferrat T, Voshol H, Juengert J, Erasimus H, Marszalek G, Kazic-Legueux M, Billy E, Ruddy DA, Stump MD, Guthy D, Ristov M, ... ... Sellers WR, et al. Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition. Cancer Research. PMID 26577700 DOI: 10.1158/0008-5472.CAN-14-3358  1
2015 Stransky N, Ghandi M, Kryukov GV, Garraway LA, Lehár J, Liu M, Sonkin D, Kauffmann A, Venkatesan K, Edelman EJ, Riester M, Barretina J, Caponigro G, Schlegel R, Sellers WR, et al. Pharmacogenomic agreement between two cancer cell line data sets Nature. 528: 84-87. PMID 26570998 DOI: 10.1038/nature15736  1
2015 Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, ... ... Sellers WR, et al. Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. Plos One. 10: e0138486. PMID 26378449 DOI: 10.1371/journal.pone.0138486  0.32
2015 Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, ... ... Sellers WR, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 28: 15-28. PMID 26175413 DOI: 10.1016/j.ccell.2015.06.006  1
2015 Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, ... ... Sellers WR, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 21: 440-8. PMID 25849130 DOI: 10.1038/nm.3841  1
2015 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. Embo Reports. 16: 280-96. PMID 25680965 DOI: 10.15252/embr.201439949  1
2015 Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, ... ... Sellers WR, et al. A distinct p53 target gene set predicts for response to the selective p53- HDM2 inhibitor NVP-CGM097 Elife. 4. DOI: 10.7554/eLife.06498  1
2014 Schoumacher M, Hurov KE, Lehár J, Yan-Neale Y, Mishina Y, Sonkin D, Korn JM, Flemming D, Jones MD, Antonakos B, Cooke VG, Steiger J, Ledell J, Stump MD, Sellers WR, et al. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer Research. 74: 3294-305. PMID 24747911 DOI: 10.1158/0008-5472.CAN-14-0138-T  1
2014 Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, ... ... Sellers WR, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Molecular Cancer Therapeutics. 13: 1117-29. PMID 24608574 DOI: 10.1158/1535-7163.MCT-13-0865  1
2014 Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, ... ... Sellers WR, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nature Medicine. 20: 87-92. PMID 24362935 DOI: 10.1038/nm.3435  1
2013 Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, ... ... Sellers WR, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America. 110: 20224-9. PMID 24277854 DOI: 10.1073/pnas.1314239110  1
2013 Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. Plos One. 8: e77652. PMID 24204904 DOI: 10.1371/journal.pone.0077652  1
2013 Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E, Wei L, Ma J, ... ... Sellers WR, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature Genetics. 45: 1386-91. PMID 24076604 DOI: 10.1038/ng.2777  1
2013 Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, ... ... Sellers WR, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Research. 73: 6024-35. PMID 23928993 DOI: 10.1158/0008-5472.CAN-13-1198  1
2013 Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discovery. 3: 1030-43. PMID 23842682 DOI: 10.1158/2159-8290.CD-13-0142  1
2013 Stuart DD, Sellers WR. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nature Medicine. 19: 538-40. PMID 23652103 DOI: 10.1038/nm.3195  1
2013 Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, ... Sellers WR, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. Plos One. 8: e61916. PMID 23613971 DOI: 10.1371/journal.pone.0061916  1
2013 Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494: 251-5. PMID 23302800 DOI: 10.1038/nature11814  1
2013 Cortés-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proceedings of the National Academy of Sciences of the United States of America. 110: 489-94. PMID 23267074 DOI: 10.1073/pnas.1212780110  1
2013 Marais R, Sellers W, Livingston D, Mihich E. Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. Cancer Research. 73: 1046-9. PMID 23222297 DOI: 10.1158/0008-5472.CAN-12-3236  1
2013 Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 899-911. PMID 23129509 DOI: 10.1002/jbmr.1810  1
2012 Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, ... ... Sellers WR, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discovery. 2: 1118-33. PMID 23002168 DOI: 10.1158/2159-8290.CD-12-0210  1
2012 Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. Plos One. 7: e44146. PMID 22952903 DOI: 10.1371/journal.pone.0044146  1
2012 Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, Yao Y, He F, Lu CX, Guagnano V, Metz T, ... ... Sellers WR, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discovery. 2: 948-59. PMID 22874768 DOI: 10.1158/2159-8290.CD-12-0237  1
2012 Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier CH, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, ... ... Sellers WR, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discovery. 2: 512-23. PMID 22684457 DOI: 10.1158/2159-8290.CD-11-0324  1
2012 Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, ... ... Sellers WR, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Molecular Cancer Therapeutics. 11: 1747-57. PMID 22653967 DOI: 10.1158/1535-7163.MCT-11-1021  1
2012 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483: 603-7. PMID 22460905 DOI: 10.1038/nature11003  1
2012 Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, Duhl D, Machajewski T, Sellers WR, Pryer NK, Gao Z. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Molecular Cancer Therapeutics. 11: 730-9. PMID 22246440 DOI: 10.1158/1535-7163.MCT-11-0667  1
2012 Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, ... ... Sellers WR, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular Cancer Therapeutics. 11: 317-28. PMID 22188813 DOI: 10.1158/1535-7163.MCT-11-0474  1
2012 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, J.Wilson C, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Sellers WR, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature. DOI: 10.1038/nature11735  1
2011 Sellers W. Q&A: William Sellers on success in small molecules. Interview by Eric Bender Cancer Discovery. 1: 543. PMID 22586672 DOI: 10.1158/2159-8290.CD-ND120811OL-10  1
2011 Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell. 147: 26-31. PMID 21962504 DOI: 10.1016/j.cell.2011.09.016  1
2011 Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proceedings of the National Academy of Sciences of the United States of America. 108: 17135-40. PMID 21949247 DOI: 10.1073/pnas.1104182108  1
2011 Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Müller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 2486-97. PMID 21812026 DOI: 10.1002/jbmr.478  1
2011 Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M, McCarthy C, ... Sellers WR, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Research. 71: 5255-64. PMID 21697284 DOI: 10.1158/0008-5472.CAN-10-4433  1
2011 Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Reviews. Drug Discovery. 10: 179-87. PMID 21358737 DOI: 10.1038/nrd3385  1
2010 Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, ... ... Sellers WR, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468: 968-72. PMID 21107320 DOI: 10.1038/nature09627  1
2010 Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, ... ... Sellers WR, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nature Medicine. 16: 1429-33. PMID 21076395 DOI: 10.1038/nm.2251  1
2010 Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, ... ... Sellers WR, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science Translational Medicine. 2: 51ra70. PMID 20881279 DOI: 10.1126/scitranslmed.3001599  1
2010 Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, ... ... Sellers WR, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proceedings of the National Academy of Sciences of the United States of America. 107: 15473-8. PMID 20713706 DOI: 10.1073/pnas.1007428107  1
2010 Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research. 70: 6804-14. PMID 20699365 DOI: 10.1158/0008-5472.CAN-10-0409  1
2010 Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, ... ... Sellers WR, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics. 42: 715-21. PMID 20601955 DOI: 10.1038/ng.619  1
2010 Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, Monahan J, Morrissey M, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Research. 70: 5528-38. PMID 20530672 DOI: 10.1158/0008-5472.CAN-09-4229  1
2010 Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical Pharmacology and Therapeutics. 87: 543-52. PMID 20237469 DOI: 10.1038/clpt.2009.297  1
2010 Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, ... ... Sellers WR, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463: 899-905. PMID 20164920 DOI: 10.1038/nature08822  1
2010 Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Research. 70: 2075-84. PMID 20160028 DOI: 10.1158/0008-5472.CAN-09-3092  1
2009 Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America. 106: 20411-6. PMID 19915144 DOI: 10.1073/pnas.0905833106  1
2009 Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, ... ... Sellers WR, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/pnas.0907325106  0.6
2009 Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. British Journal of Cancer. 101: 1218-9; author reply. PMID 19738612 DOI: 10.1038/sj.bjc.6605301  1
2009 Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Molecular and Cellular Biology. 29: 5377-88. PMID 19635806 DOI: 10.1128/MCB.01649-08  1
2009 Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, ... ... Sellers WR, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 16: 21-32. PMID 19573809 DOI: 10.1016/j.ccr.2009.04.012  1
2009 Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research. 69: 4674-81. PMID 19470766 DOI: 10.1158/0008-5472.CAN-09-0146  1
2009 Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research. 69: 4286-93. PMID 19401449 DOI: 10.1158/0008-5472.CAN-08-4765  1
2009 Stuart D, Sellers WR. Linking somatic genetic alterations in cancer to therapeutics. Current Opinion in Cell Biology. 21: 304-10. PMID 19328671 DOI: 10.1016/j.ceb.2009.02.001  1
2009 Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, ... ... Sellers WR, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 106: 4834-9. PMID 19261849 DOI: 10.1073/pnas.0806514106  1
2009 Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, ... ... Sellers W, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1417-27. PMID 19193619 DOI: 10.1158/1078-0432.CCR-08-1564  1
2009 Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, Sellers WR, Benson JD. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (Georgetown, Tex.). 8: 498-504. PMID 19177017  1
2009 Zhu J, Recio-Pinto E, Hartwig T, Sellers W, Yan J, Thornhill WB. The Kv1.2 potassium channel: the position of an N-glycan on the extracellular linkers affects its protein expression and function. Brain Research. 1251: 16-29. PMID 19056359 DOI: 10.1016/j.brainres.2008.11.033  1
2008 Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 27: 5511-26. PMID 18794885 DOI: 10.1038/onc.2008.246  1
2008 Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, ... ... Sellers WR, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Research. 68: 6779-88. PMID 18701503 DOI: 10.1158/0008-5472.CAN-08-0742  1
2008 Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, ... ... Sellers WR, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 14: 146-55. PMID 18691549 DOI: 10.1016/j.ccr.2008.06.002  1
2008 Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, ... Sellers W, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. 7: 1851-63. PMID 18606717 DOI: 10.1158/1535-7163.MCT-08-0017  1
2008 Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, ... ... Sellers WR, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 105: 8713-7. PMID 18552176 DOI: 10.1073/pnas.0803379105  1
2008 Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M. Major copy proportion analysis of tumor samples using SNP arrays. Bmc Bioinformatics. 9: 204. PMID 18426588 DOI: 10.1186/1471-2105-9-204  1
2008 Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Molecular and Cellular Biology. 28: 3281-9. PMID 18332125 DOI: 10.1128/MCB.00310-08  1
2008 Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Research. 36: 2446-56. PMID 18304946 DOI: 10.1093/nar/gkn089  1
2008 Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research. 68: 664-73. PMID 18245465 DOI: 10.1158/0008-5472.CAN-07-2615  1
2008 Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 32: 307-16. PMID 18202752  1
2008 Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel Cancer Research. 68: 589-596. PMID 18199556 DOI: 10.1158/0008-5472.CAN-07-1570  1
2007 Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, ... ... Sellers WR, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Research. 67: 11493-8. PMID 18089776 DOI: 10.1158/0008-5472.CAN-07-5173  1
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Sellers WR, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/pnas.0710052104  1
2007 Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proceedings of the National Academy of Sciences of the United States of America. 104: 17771-6. PMID 17978178 DOI: 10.1073/pnas.0708476104  1
2007 Hill AD, Chang BS, Hill RS, Garraway LA, Bodell A, Sellers WR, Walsh CA. A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome. American Journal of Medical Genetics. Part A. 143: 1692-8. PMID 17603806 DOI: 10.1002/ajmg.a.31776  1
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Sellers WR, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/ng1975  1
2007 Garraway LA, Sellers WR. The authors reply [2] Nature Reviews Cancer. 7: 1P. DOI: 10.1038/nrc1947-c2  1
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Sellers WR, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/journal.pmed.0030485  1
2006 Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, ... Sellers WR, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research. 66: 8337-41. PMID 16951139 DOI: 10.1158/0008-5472.CAN-06-1482  1
2006 Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Molecular Cell. 23: 575-87. PMID 16916644 DOI: 10.1016/j.molcel.2006.06.028  1
2006 Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews. Cancer. 6: 593-602. PMID 16862190 DOI: 10.1038/nrc1947  1
2006 Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, ... ... Sellers WR, et al. Development of an integrated prostate cancer research information system. Clinical Genitourinary Cancer. 5: 61-6. PMID 16859581 DOI: 10.3816/CGC.2006.n.019  1
2006 Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, ... ... Sellers WR, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine. 12: 852-5. PMID 16799556 DOI: 10.1038/nm1437  1
2006 Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C. Validating cancer drug targets. Nature. 441: 451-6. PMID 16724057 DOI: 10.1038/nature04873  1
2006 Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. Plos Computational Biology. 2: e41. PMID 16699594 DOI: 10.1371/journal.pcbi.0020041  1
2006 Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Research. 66: 3162-8. PMID 16540667 DOI: 10.1158/0008-5472.CAN-05-3757  1
2006 Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America. 103: 3633-8. PMID 16537447 DOI: 10.1073/pnas.0510570103  1
2006 Garraway LA, Sellers WR. From integrated genomics to tumor lineage dependency. Cancer Research. 66: 2506-8. PMID 16510564 DOI: 10.1158/0008-5472.CAN-05-4604  1
2006 Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 439: 358-62. PMID 16273091 DOI: 10.1038/nature04304  1
2005 Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 73-81. PMID 16869740 DOI: 10.1101/sqb.2005.70.056  1
2005 Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harbor Symposia On Quantitative Biology. 70: 25-34. PMID 16869735 DOI: 10.1101/sqb.2005.70.016  1
2005 Mihich E, Sellers WR. Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumors. Cancer Research. 65: 11251-4. PMID 16357127 DOI: 10.1158/0008-5472.CAN-05-2920  1
2005 LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M. Allele-specific amplification in cancer revealed by SNP array analysis. Plos Computational Biology. 1: e65. PMID 16322765 DOI: 10.1371/journal.pcbi.0010065  1
2005 Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 24: 7465-74. PMID 16288293 DOI: 10.1038/sj.onc.1209096  1
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Sellers WR, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/NEJMoa051918  1
2005 Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Research. 65: 8968-74. PMID 16204070 DOI: 10.1158/0008-5472.CAN-05-1829  1
2005 Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. Plos Medicine. 2: e313. PMID 16187797 DOI: 10.1371/journal.pmed.0020313  1
2005 Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, ... Sellers WR, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes, Chromosomes & Cancer. 44: 351-64. PMID 16080200 DOI: 10.1002/gcc.20249  1
2005 Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proceedings of the National Academy of Sciences of the United States of America. 102: 11355-60. PMID 16051706 DOI: 10.1073/pnas.0500165102  1
2005 Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, ... ... Sellers WR, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436: 117-22. PMID 16001072 DOI: 10.1038/nature03664  1
2005 Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, ... ... Sellers WR, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Research. 65: 5561-70. PMID 15994928 DOI: 10.1158/0008-5472.CAN-04-4603  1
2005 Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, ... ... Sellers WR, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7: 387-97. PMID 15837627 DOI: 10.1016/j.ccr.2005.03.023  1
2005 Krützfeldt M, Ellis M, Weekes DB, Bull JJ, Eilers M, Vivanco MD, Sellers WR, Mittnacht S. Selective ablation of retinoblastoma protein function by the RET finger protein. Molecular Cell. 18: 213-24. PMID 15837424 DOI: 10.1016/j.molcel.2005.03.009  1
2005 Sellers WR, Meyerson M. EGFR gene mutations: a call for global x global views of cancer. Journal of the National Cancer Institute. 97: 326-8. PMID 15741561 DOI: 10.1093/jnci/dji079  1
2005 Garraway LA, Sellers WR. Array-based approaches to cancer genome analysis Drug Discovery Today: Disease Mechanisms. 2: 171-177. DOI: 10.1016/j.ddmec.2005.05.020  1
2004 Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Research. 64: 8867-75. PMID 15604246 DOI: 10.1158/0008-5472.CAN-04-2938  1
2004 Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, ... ... Sellers WR, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research. 64: 8816-20. PMID 15604238 DOI: 10.1158/0008-5472.CAN-04-1923  1
2004 D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH, Iversen P, Gelmann EP, Sellers WR. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy Journal of Urology. 172: S42-S47. PMID 15535442 DOI: 10.1097/01.ju.0000141845.99899.12  1
2004 Oh WK, Kantoff PW, Sellers WR, Rosen N. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer Journal of Urology. 172: S34-S37. PMID 15535440 DOI: 10.1097/01.ju.0000141674.92253.fe  1
2004 Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, et al. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. The Journal of Urology. 172: S3-5. PMID 15535434 DOI: 10.1097/01.ju.0000142276.19511.ac  1
2004 Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Molecular Cancer Research : McR. 2: 489-94. PMID 15383627  1
2004 Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 6: 263-74. PMID 15380517 DOI: 10.1016/j.ccr.2004.06.027  1
2004 Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. The Journal of Urology. 172: 1134-9. PMID 15311057 DOI: 10.1097/01.ju.0000136526.78535.b8  1
2004 Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6: 17-32. PMID 15261139 DOI: 10.1016/j.ccr.2004.06.010  1
2004 Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2954-63. PMID 15254063 DOI: 10.1200/JCO.2004.02.141  1
2004 Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, ... ... Sellers WR, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 104: 1855-8. PMID 15178581 DOI: 10.1182/blood-2004-02-0712  1
2004 Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Research. 64: 3814-22. PMID 15172988 DOI: 10.1158/0008-5472.CAN-03-3881  1
2004 Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine. 10: 594-601. PMID 15156201 DOI: 10.1038/nm1052  1
2004 Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, Li C, Meyerson M, Sellers WR. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Research. 32: e71. PMID 15150323 DOI: 10.1093/nar/gnh069  1
2004 Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research. 64: 3060-71. PMID 15126342 DOI: 10.1158/0008-5472.CAN-03-3308  1
2004 Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, N.Y.). 304: 1497-500. PMID 15118125 DOI: 10.1126/science.1099314  1
2004 Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (Oxford, England). 20: 1233-40. PMID 14871870 DOI: 10.1093/bioinformatics/bth069  1
2004 Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Research. 32: 893-901. PMID 14769947 DOI: 10.1093/nar/gkh238  1
2004 Iversen P, DAmico AV, Gelmann EP, Sellers WR. Discussion Journal of Urology. 172: S50-S51. DOI: 10.1097/01.ju.0000141712.79986.77  1
2003 Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4: 463-76. PMID 14706338 DOI: 10.1016/S1535-6108(03)00303-9  1
2003 Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH, Nelson JB, Sellers WR, Roach M, Kantoff PW, Oh WK, Smith MR. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen Journal of Urology. 170: S84-S89. PMID 14610416 DOI: 10.1097/01.ju.0000095151.97404.7c  1
2003 Blackledge G, Sellers WR, Smith MR. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy Journal of Urology. 170: S77-S83. PMID 14610415 DOI: 10.1097/01.ju.0000095022.80033.d3  1
2003 Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. The Journal of Urology. 170: S65-7; discussion S6. PMID 14610413 DOI: 10.1097/01.ju.0000096372.07687.86  1
2003 Smith MR, Kantoff PW, Carroll PR, Benaron DA, Sellers WR, Higano CS. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer Journal of Urology. 170: S55-S58. PMID 14610411 DOI: 10.1097/01.ju.0000095102.34708.bc  1
2003 Roach M, Kantoff PW, D'Amico AV, Sellers WR, Higano CS. Hormonal therapy and radiotherapy for localized prostate cancer: Who, where and how long? Journal of Urology. 170: S35-S41. PMID 14610408 DOI: 10.1097/01.ju.0000096516.41893.c6  1
2003 Oh WK, Roach M, Smith MR, Sellers WR, Kantoff PW, Carroll PR, Higano CS. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer Journal of Urology. 170: S28-S34. PMID 14610407 DOI: 10.1097/01.ju.0000095356.02647.64  1
2003 Febbo PG, Sellers WR. Use of expression analysis to predict outcome after radical prostatectomy. The Journal of Urology. 170: S11-9; discussion S1. PMID 14610405 DOI: 10.1097/01.ju.0000095567.03807.a1  1
2003 Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, et al. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. The Journal of Urology. 170: S3-5. PMID 14610403 DOI: 10.1097/01.ju.0000095101.18470.a0  1
2003 Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4: 147-58. PMID 12957289 DOI: 10.1016/S1535-6108(03)00187-9  1
2003 Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Research. 63: 4781-5. PMID 12941794  1
2003 Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proceedings of the National Academy of Sciences of the United States of America. 100: 7841-6. PMID 12799464 DOI: 10.1073/pnas.1232229100  1
2003 Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treatment and Research. 115: 145-67. PMID 12613196  1
2002 Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Research. 62: 6803-7. PMID 12460888  1
2002 Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell. 2: 349-50. PMID 12450788 DOI: 10.1016/S1535-6108(02)00187-3  1
2002 Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2: 81-91. PMID 12150827 DOI: 10.1016/S1535-6108(02)00086-7  1
2002 Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1: 203-9. PMID 12086878 DOI: 10.1016/S1535-6108(02)00030-2  1
2002 Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 21: 4099-107. PMID 12037666 DOI: 10.1038/sj.onc.1205562  1
2001 Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. The Journal of Biological Chemistry. 276: 48627-30. PMID 11707428 DOI: 10.1074/jbc.C100556200  1
2000 Siegert JL, Rushton JJ, Sellers WR, Kaelin WG, Robbins PD. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 19: 5703-11. PMID 11126356 DOI: 10.1038/sj.onc.1203966  1
2000 Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Molecular and Cellular Biology. 20: 8969-82. PMID 11073996 DOI: 10.1128/MCB.20.23.8969-8982.2000  1
2000 Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Molecular and Cellular Biology. 20: 8889-902. PMID 11073989 DOI: 10.1128/MCB.20.23.8889-8902.2000  1
2000 Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. The Journal of Biological Chemistry. 275: 39223-30. PMID 11010972 DOI: 10.1074/jbc.M007291200  1
2000 Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function Molecular and Cellular Biology. 20: 5010-5018. PMID 10866658 DOI: 10.1128/MCB.20.14.5010-5018.2000  1
2000 Vazquez F, Sellers WR. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3- kinase signaling Biochimica Et Biophysica Acta - Reviews On Cancer. 1470: M21-M35. PMID 10656987 DOI: 10.1016/S0304-419X(99)00032-3  1
2000 Ramaswamy S, Sellers WR. PTEN: A prostate cancer tumor-suppressor gene Prostate Journal. 2: 55-61. DOI: 10.1046/j.1525-1411.2000.22001.x  1
1999 Sellers WR, Fisher DE. Apoptosis and cancer drug targeting Journal of Clinical Investigation. 104: 1655-1661. PMID 10606616  1
1999 McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Research. 59: 4291-4296. PMID 10485474  1
1999 Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/akt pathway Proceedings of the National Academy of Sciences of the United States of America. 96: 2110-2115. PMID 10051603 DOI: 10.1073/pnas.96.5.2110  1
1999 Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW, Taya Y, Kaelin WG. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Molecular and Cellular Biology. 19: 1068-80. PMID 9891042  1
1998 Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin WG. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes & Development. 12: 95-106. PMID 9420334  1
1998 Kaelin WG, Adams PD, Fine HA, Mivake S, Sellers WR. Control of cell-growth and differentiation by the cyclin/cdk/rb pathway Faseb Journal. 12: A1326.  1
1997 Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer Journal of Clinical Oncology. 15: 3301-3312. PMID 9363859  1
1997 Adams PD, Lopez P, Sellers WR, Kaelin WG. Fluorescence-activated cell sorting of transfected cells Methods in Enzymology. 283: 59-72. PMID 9251011 DOI: 10.1016/S0076-6879(97)83007-8  1
1996 Neuman E, Sellers WR, McNeil JA, Lawrence JB, Kaelin WG. Structure and partial genomic sequence of the human E2F1 gene. Gene. 173: 163-9. PMID 8964493 DOI: 10.1016/0378-1119(96)00184-9  1
1996 Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors Molecular and Cellular Biology. 16: 6623-6633. PMID 8943316  1
1996 Grafi G, Burnett RJ, Helentjaris T, Larkins BA, Decaprio JA, Sellers WR, Kaelin WG. A maize cDNA encoding a member of the retinoblastoma protein family: Involvement in endoreduplication Proceedings of the National Academy of Sciences of the United States of America. 93: 8962-8967. PMID 8799136 DOI: 10.1073/pnas.93.17.8962  1
1996 Sellers WR, Kaelin WG. RB [corrected] as a modulator of transcription Biochimica Et Biophysica Acta. 1288: M1-5. PMID 8764839  1
1996 Sellers WR, Kaelin WG. xRB as a modulator of transcription Biochimica Et Biophysica Acta - Reviews On Cancer. 1288: M1-M5. DOI: 10.1016/0304-419X(96)00014-5  1
1995 Sellers WR, Rodgers JW, Kaelin WG. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites Proceedings of the National Academy of Sciences of the United States of America. 92: 11544-11548. PMID 8524800 DOI: 10.1073/pnas.92.25.11544  1
1995 Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG. The transcription factor E2F-1 is a downstream target of RB action. Molecular and Cellular Biology. 15: 742-55. PMID 7823942  1
1995 Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 375: 694-8. PMID 7791904 DOI: 10.1038/375694a0  1
1995 Neuman E, Flemington EK, Sellers WR, Kaelin WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter Molecular and Cellular Biology. 15: 4660. PMID 7623859  1
1994 Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell. 77: 799-800. PMID 8004670 DOI: 10.1016/0092-8674(94)90127-9  1
1992 Kaelin WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell. 70: 351-64. PMID 1638635 DOI: 10.1016/0092-8674(92)90108-O  1
Show low-probability matches.